TIDMPRM

RNS Number : 6681J

Proteome Sciences PLC

30 June 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Stroke Diagnostic Presentation at EuroMedLab 2017 - Research Milestone Achieved

We are pleased to announce that Randox Laboratories Ltd, ("Randox") presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.

In a study of 192 individuals, led by Dr. Konstantinos Makris of KAT General Hospital, Athens, Greece, the Randox Rapid Stroke Array showed excellent performance in identifying stroke from mimic conditions and healthy controls, and in differentiating between ischaemic and haemorrhagic strokes.

With the presentation of these data, Randox and Proteome Sciences have agreed that a pre-established milestone for the delivery of a stroke array for research purposes has now been achieved and an associated payment of GBP100,000 will be made by Randox according to the contractual terms initially agreed in April 2012.

Commenting on the presentation, Dr Ian Pike, Chief Scientific Officer at Proteome Sciences, said: "The results from the first trial of the Randox Rapid Stroke Array are very encouraging and have confirmed the potential of biomarkers to provide clinicians with a clearer diagnosis and to improve patient management."

John Lamont, Chief Scientist at Randox, said: "We are extremely pleased with the outcome of this study and look forward to the completion of a prospective registration trial which is currently being planned."

 
 For further information: 
 
  Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive Officer Tel: 
  +44 (0)20 7043 2116 
 Dr Ian Pike, Chief Scientific 
  Officer 
 Geoff Ellis, Finance Director 
 
   finnCap Limited (Nominated 
   Adviser/Broker)                 Tel: +44 (0)20 7220 
   Geoff Nash/James Thompson       0500 
 Tony Quirke (broking) 
 
  IFC Advisory (Financial PR and IR) 
 Tim Metcalfe/Graham                        Tel: +44 (0)20 3053 
  Herring/Miles Nolan                        8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESSEUESUFWSEEM

(END) Dow Jones Newswires

June 30, 2017 02:01 ET (06:01 GMT)

Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Proteome Sciences Charts.
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Proteome Sciences Charts.